TABLE 4.
Bioactive compound/ Herbal derivative | Cell type/Model | Test and oosage | Anti-tumour outcome | Molecular outcome | References |
---|---|---|---|---|---|
PubChem CID (Class) | |||||
Source | |||||
Curcumin | In vitro: MDA 1986 (OSCC), Tu 686 (LSCC), Tu 167, JMAR C42 (Floor of mouth OSCC), MDA 686LN (OPSCC) | Cell proliferation: 10 μM, 50 μM | • Proliferation↓ | • NF-κB activation↓ | Aggarwal et al. (2004) |
CID- 969516 | • Apoptosis↑ | • Bcl-2↓, cyclin D1↓, IL-6↓, COX-2↓, MMP-9↓ | |||
(Phenolics) | • Arrests cell cycle in G1/S phase | ||||
Curcuma Longa | |||||
Gossypol | In vitro: UMSCC-1, UMSCC-17B (Floor of mouth OSCC), Human oral keratinocytes and Normal keratinocytes | Cell proliferation: | • Proliferation↓ | NA | Wolter et al. (2006) |
CID- 3503 | UMSCC-1, UMSCC-17B, Human oral keratinocytes and Normal keratinocytes IC50- 3, 6,2, 12.5 μM respectively | • Growth of tumour↓ | |||
Phenolic | • Mitotic rate↓ | ||||
Gossypium arboreum L. | In vivo: NCr-nu/nu mice | • Apoptosis↑ | |||
Berberine | In vitro: HSC-3 (Tongue OSCC) | Cell viability: | • Cell viability↓ | • Bcl-2↓, BAX↑, p53↑ | Lin et al. (2007) |
CID: 2353 | 10 μM | • G0/G1-phase arrest | • Cyt C release | ||
(Alkaloid) | • ROS↑,Ca2+↑, MMP↓, Apoptosis↑ | ||||
Rhizoma coptidis | |||||
In-vitro study: FADU (Hypopharyngeal SCC) | Cell cytotoxicity: | • Cytotoxicity ↑ | • FasL ↑, TRAIL ↑ | Seo et al. (2015) | |
• Cleaved caspase-8 ↑, cleaved | |||||
12 or 25 μM for 24 h | • Apoptosis ↑ | • caspase-7 ↑ | |||
• Cell viability ↓ | • Bcl-2 ↓, Bcl-xL ↓, Bax ↑, Bad ↑, Apaf-1↑, cleaved caspase-9 ↑, cleaved caspase-3 ↑, PARP ↑ | ||||
• Cell migration ↓ | |||||
• MMP-2 ↓, MMP-9 ↓ | |||||
• ERK, JNK and p38 phosphorylation ↓ | |||||
Physalis angulate | In-vitro study: HSC-3 (OSCC) | Cell viability: | • Mitochondrial reductase activity ↓ | • ROS ↑ | Lee et al. (2009) |
• Apoptosis ↑ | • Bcl2 ↓, Bax ↓, AIF ↓, cytochrome c ↓, proform caspase-3 protein levels ↓, caspase-9 ↑, proform caspace-4 protein levels ↑, MMP attenuated | ||||
(Crude extract) | IC50: 10 μg/ml | • Oxidative stress ↑ | |||
• Loss of cell function ↑ | |||||
• ORP150 ↓, HSP70 ↑ | |||||
• S- and G2/M-phase arrest | • HO-1 ↑, SOD ↑ | ||||
• Mitochondrial function impaired | |||||
Guggulsterone | In vitro: SCC-4 (Tongue OSCC), HSC-2 (OSCC) | Protein expression: | NA | • Phosphorylation of p65, IkBα & STAT3, NF-κB↓ | |
CID- 6450278 | 50 μM | ||||
(3-hydroxy steroid) | • IL-6↓ , COX-2↓ | ||||
Commiphora mukul | • Expression VEGF↓ | ||||
Proanthocyanidins | In vitro: UMSCC-1, UMSCC-5 (Floor of mouth OSCC), FaDu (Hypopharyngeal OSCC), OSC-19 (Tongue OSCC), Beas-2B (Bronchial Epithelium transformed with Ad12-SV40 2B) | In vitro: IC50- 101 nM, 67 nM for | • Cell viability↓ | • Cyclin D1↓ and Cyclin D2↓ | Prasad and Katiyar, (2012) |
CID- 108065 | 24 and 48 hrs, respectively | • Apoptosis↑ | • cdk2↓, cdk4↓, cdk6↓ | ||
• G1 phase arrest | • Cip1/p21↑ and Kip1/p27↑ | ||||
In vivo: 0.5%, w/w | • 61% less tumor volume (p<0.001) | • Bax↑, Bcl-2↓, caspase 3↑ and poly(ADP-ribose)polymerase↑. | |||
(Phenolic) | |||||
Vitis vinifera | |||||
In vivo: athymic nude mice | |||||
Wogonin | In vitro: NPC-TW076, NPCTW039 (NPSCC) | Autophagy: 50 μM | • Autophagy↑ | • P13K/Akt↓, mTOR/P70S6K↓, c-Raf/ERK↓ | Chow et al. (2012) |
CID- 5281703 | • Apoptosis↑ | ||||
(Phenolic) | |||||
Scutellaria baicalensis | |||||
Caffeic Acid Phenethyl Ester | In vitro: TW2.6 (OSCC) | Cell proliferation: IC50- 83.8, 46.6, and 18.8 μM for 24, 48, and 96 h treatment, respectively | • Cell proliferation↓, colony formation↓ | • Akt↓, GSK3β↓, FOXO1↓, FOXO3a↓, NF-κB↓, Rb↓, Skp2↓, cyclin D1↓, p27Kip↑ | Kuo et al. (2013) |
CID- 5281703 | • Apoptosis↑ | ||||
(Phenolic) | • G1 phase↓, G2/M phase↑ cell population | ||||
Populus nigra L. | |||||
Ellagic acid | In vitro: HSC-2 (OSCC), HF-1 (Normal fibroblasts) | Cytotoxicity: (IC50- 260 & 142 μM on 2nd and 3rd day of exposure, respectively) | • Apoptosis↑ | • Caspase 3/7 ↑ | Weisburg et al. (2013) |
CID- 5281855 | • Cleavage of poly ADP ribose polymerase | ||||
(Phenolic) | |||||
Rubus occidentalis | |||||
Cucurbitacin | In vitro: | Cytotoxicity: IC50- 3.7 μM | • Sub G0/G1 phase arrest | • Caspase 3 Activation | Hung et al. (2013) |
CID- 5281316 | SAS (Tongue OSCC) | • Apoptosis↑ | • MMP↓ | ||
(Terpene) | |||||
Cucumic melo L | |||||
BME | In vitro: Cal-27 (Tongue OSCC), JHU-22, JHU-29 (Laryngeal SCC) | In vitro: 1% BME | • Cell proliferation↓ | • c-Met signaling pathway↓ | Rajamoorthi et al. (2013) |
(crude extract) | In vivo: 100 μl BME (0.1 g/ml) for 5 days | • Tumor growth and volume↓ | • Mcl-1, pSTAT3, cMyc expression↓ | ||
Momordica charantia | • Keratinocyte formation↓, mitosis↓ | • cyclinD1↓, survivin↓, cell arrest | |||
In vivo: BALB/c athymic nude mice | • MCM2↓ | ||||
Honokiol | In vitro: SCC-1, SCC- 5 (Floor of mouth OSCC), OSC-19 (Tongue OSCC), FaDu (Hypopharyngeal SCC) | In vitro: ∼60 μM for 24, 48 and 72 hrs | • Cell viability↓ | • Expression levels of Cyclins: D1, D2, and Cdks: 4 and 6↓ | Singh et al. (2015) |
CID-72303 | • Apoptosis↑ | ||||
(Phenolic) | In vivo: 100 mg/kg body weight (mw-266.3) | • EGFR↓, mTOR and their downstream signalling molecules↓ | |||
Magnolia officinalis | |||||
Cepharanthine | In vitro: CNE-1, CNE-2 (NPSCC) | Cell proliferation: | • Cell proliferation↓ | • DNA repair genes ↓ | Liu et al. (2015) |
CID- 10206 | IC50 for CNE-1 and CNE-2: 20 and 32 nM after 48 hrs, respectively | • G1 phase arrest | |||
(Alkaloid) | |||||
Stephania cepharantha | |||||
MEAG | In vitro: MC3 (Chronic myelogenous leukemia), HN22 (OSCC) | Cytotoxic effect: | • Mitochondria mediated apoptosis↑ | • MMP↓, Cyt C release, caspase 9 ↑, t-Bid↑, cleaved caspase-8↑, DR5↑. | Lee et al. (2016) |
(Crude extract) | IC50 for MC3 and HN22: 6.5 and 4.6 μg/ml, respectively | ||||
(Terpenes) | • Nuclear condensation and fragmentation | ||||
Withania somnifera | |||||
Goniothalamin | In vitro: H400 (OSCC) | Cytotoxic effect: | • Cell viability↓ | • MMP↓, Cyt C release | Li et al. (2016) |
CID- 6440856 | IC50: 8.9 nM after 72 h | • Cell proliferation↓ | • NF-κB activation↓ | ||
(Phenolic) | • Apoptotic-like morphology (cell shrinkage, dense cytoplasm, blebbing of cell surface) | ||||
Goniothalamus marcrophyllus | |||||
• S phase arrest. | |||||
Lupeol | In vitro: | Cell viability: | • G1 phase arrest | • Expression p53↑, Bax↑, CDKN2A↑, CyclinD1↓, Ki67↓ | Bhattacharyya et al. (2017) |
CID- 259846 | HEp-2 (Human papillomavirus-related endocervical adenocarcinoma), UPCI:SCC131 (Floor OSCC) | IC50 for Hep-2 and SCC131: 53.5 and 52.4 μM after 24 hrs, respectively | • Apoptosis↑ via intrinsic pathway | ||
(Terpene) | • Cell viability↓ | • Caspase 3 activation | |||
Camellia japonica | |||||
Ex vivo: Fresh HNSCC tumor tissues | |||||
Icaritin | In vitro: KB (Human papillomavirus-related endocervical adenocarcinoma), SCC9 (Tongue OSCC) | Cell viability: | • Mitochondria mediated apoptosis↑ | • MMP↓, Cyt c release | Jin et al. (2017) |
CID- 5318980 | ∼20 μM for 24 and 48 h | • miR-124↑ | |||
(Phenolic) | • Sp1/DNMT1 signaling↓ | ||||
Epimedium grandiflorum | |||||
Osmuda regalis root | In vitro: FaDu (Hypopharyngeal SCC), HLaC78, HLaC79, HLaC79-tax (LSCC) | Cytotoxicity: | • Cell growth↓ | • CLEC3B↓, KAL1↓, MMP 11↓, MMP 15↓, MMP2↓ | Schmidt et al. (2017) |
(crude extract) | IC50 for HLaC79, FaDu, HLaC79-Tax and HLaC79: 21.4, 8.5, 20.6 and 9.9 μg/ml, respectively | • Apoptosis↑ | |||
Osmuda regalis | • Invasion↓ | • Integrin such as ITGB3↑, ITGA1↑, ITGAM↑ | |||
• metastasis genes such as CTFG↑, PPIA↑, SELP↑, VCAN↑ | |||||
Piperine | In vitro: KB (Human papillomavirus-related endocervical adenocarcinoma) | Cell proliferation: | • Apoptosis↑ | • ROS↑, MMP↓ | Siddiqui et al. (2017) |
CID- 638024 | IC50: 124 μM for 24 h | • Cell viability↓ | • Caspase 3 activation | ||
(Alkaloid) | • Cell growth↓ | ||||
Piper nigrum | • Cellular morphological changes | ||||
• G2/M phase arrest | |||||
Embelin | In vitro: SCC25, Cas9-22, YD10B (Tongue squamous cell carcinoma) | Cytotoxicity: | • Cell viability↓ | • MMP↓, caspase 9 & 3↓ | Lee et al. (2017) |
0–300 μM for 24 h; cell specific effect | • Condensed fragmented nuclei | • p62/SQSTM1↓ | |||
• Autophagic vacuoles appears | • Conversion↑ LC3-I to LC3-II | ||||
CID- 32798 | |||||
(Phenolic) | |||||
Embelia ribes | |||||
Dihydroartemisinin | In vitro: Cal-27 (Tongue OSCC) | Cell proliferation: | • Autophagosomes↑ | • LC3-II ↑, Bevlin-1↑, γH2AX foci↑ | Shi et al. (2017) |
CID- 3000518 | IC50: 24.4 μM for 24 h | • Oxidative stress↑ | • STAT3 activation↓ and disrupted p-STAT3 nuclear translocation | ||
• DNA double-strand break | |||||
(Sesquiterpene lactone) | • Weight and volume of Xenograft tumor↓ by 56.58% | ||||
Artemisia annua | |||||
β-Elemene | In vitro: YD-38 (Gingival OSCC) | Colony formation and Apoptosis: | • Cell proliferation↓ | • Expressions of STAT3↓, p-STAT3↓, p-JAK2↓, and Bcl-2↓, Bax↑ and caspase-3↑ | Huang and Yu, (2017) |
CID- 6918391 | In vivo: BALB/c nude mice | • Apoptosis↑ | |||
(Terpene) | 195 nM β-Elemene | ||||
Curcuma wenyujin | • Block JAK2-STAT3 pathway | ||||
Thymol | In vitro: Cal27, SCC-4, SCC-9 (Tongue OSCC) | Cytotoxicity: | • Cell viability↓ | • c-PARP↑, MMP dysfunction | De La Chapa et al. (2018) |
CID- 6989 | In vivo: Athymic nu/nu mice | 2.3 µM | • No colony formation | ||
(Terpene) | • In vivo tumor growth↓ | ||||
Thymus vulgaris | • Apoptosis↑ | ||||
Tanshinone | In vitro: SCC-9 (Tongue OSCC) | Cell viability: | • Apoptosis↑ | • LC3-I↑ | Qiu et al. (2018) |
CID- 114917 | In vivo: BALB/c-nu | IC50: 17.5 μM. | • Autophagy↑ | • Beclin-1/Atg7/Atg12-Atg5 pathway↑ | |
(Abietane diterpenoid) | • Growth of solid tumors in vivo | • PI3K/Akt/mTOR pathway↓ | |||
Salvia miltiorrhiza | |||||
Oridonin | In vitro: UM1, SCC25 (Tongue OSCC) | Cell proliferation: | • G2/M phase arrest | • Bax/Bcl-2↑ | Yang et al. (2018b) |
CID- 5321010 | IC50 for SCC25, UM1, UM2, HSC3 and Ca127: 9.1, 8.2, 10.6, 15.4 and 9.6 μM, respectively. | • Apoptosis↑ | • Cyclin B1↓, pCDK1↑, cyclin D1↑, cyclin D3↑, p21↑ and cyclin A2↑ | ||
(Terpene) | |||||
Rabdosia rubescens | • Activates caspase-3, caspase-9 and PARP-1 | ||||
• P13K/Akt/mTOR pathway↓ | |||||
Epigallocatechin-3-gallate | In vitro: HSC (Tongue OSCC) | Cell proliferation: | • Cell viability↓ | • Caspase‑3 and -7↑ | Yoshimura et al. (2019) |
In vivo: BALB/c nude (nu/nu) mice | IC50 value at 24, 48 and 72 h were >100, 43.2 and 39.3 μM, respectively | • G1 phase arrest | • miR-22↑ | ||
CID- 65064 | • Apoptosis↑ | ||||
(Phenolic) | • Tumor size↓ 45.2% | ||||
Camellia sinensis | |||||
Quercetin | In vitro: hNOK (Human normal oral keratinocytes), Tc8113, SAS (Tongue OSCC) | Cell viability: | • Cell viability↓ | • miR-22/WNT1/Beta-catenin pathway↓ | Zhang et al. (2019) |
(Phenolic) | CC50 for hNOK, Tc8113 & SAS: 298.6, 48.7 & 44.3 mM, respectively | • Tumor volume and weight↓ | |||
CID: 5280343 | |||||
Allium cepa L. | |||||
In vivo: BALB/c nu/nu mice | |||||
Ursolic Acid | In vitro: Ca9-22 (Tongue OSCC), SCC2095 (OSCC) | Cell proliferation: | • Caspase-dependent apoptosis | • Akt/mTOR/NF-κB signaling↓, ERK↓, and p38↓ | Lin et al. (2019) |
CID- 64945 | IC50 for UA, Ca9-22: 11.5 and 13.8 μM, respectively | • Autophagy↑, autophagosomes↑ | |||
(Terpene) | • Migration↓, Invasion↓ | • LC3B-II conversion, p62↑ | |||
Salvia rosmarinus | • Proteolytic activity of MMP-2↓ | ||||
Shikonin | In vitro: 5-8F (NPSCC) | Cell proliferation: | • Necroptosis↑ | • Necrostatin-1↑ | Liu et al. (2019) |
CID- 479503 | In vivo: BALB/c nude mice | IC50: 7.5 μM after 6 h | • In vivo tumor growth↓ | • RIPK1↑, RIPK3↑, MLKL↑ | |
(Hydroxy-1,4-naphthoquinone) | • Caspase-8 and -3↑ | ||||
• ROS↑ | |||||
Lithospermum erythrorhizon | |||||
Chrysophanol | In vitro: FaDu (Hypopharyngeal SCC), SAS (Tongue OSCC) | Cell viability: | • Cell viability↓ | • ROS↑ | Hsu et al. (2020) |
CID- 10208 | IC50 for FaDu and SAS: 9.6 ± 1.3 and 12.6 ± 2.1 μm at 24 h, respectively | • G1 phase arrest | • Expression of procaspase 3↓, cyclin D1↓, CDK4↓, CDK2↓, cdc2↓ | ||
(Phenolic) | • Metastasis↓, EMT↓ | ||||
Rheum rhabarbarum | |||||
Moscatilin | In vitro: FaDu (Hypopharyngeal SCC) | Cell cytotoxicity: | • Cell viability↓ | • Activation of caspases-3,-8,-9,-7↑ | Lee et al. (2020) |
CID- 176096 | IC50: 1.4 μM at 72 h | • Cell proliferation↓ | • MMP↓, Cyt C release | ||
(Phenolic) | • Apoptosis via intrinsic as well as extrinsic pathway | • JNK pathway↓ | |||
Dendrobium sp. | |||||
Demethoxycurcumin | In vitro: | Cell proliferation: | • Cell viability↓ | • cIAP1/XIAP↓, heme oxygenase-1↑ | Chien et al. (2020) |
SCC-9, HSC-3 (Tongue SCC) | IC50: 50 μM | • Cell proliferation↓ | • Caspase-3↑, -9↑, -8↑, p38-MAPK-HO-1 signaling↑, MAPK↑, JNK1/2↑ | ||
CID- 5469424 | • G2/M phase arrest | ||||
(Phenolic) | • Morphological changes | ||||
Curcuma Longa |
Abbreviations: Akt- Protein kinase B; Apaf-1- Apoptotic protease activating factor 1; Atg7- Autophagy related 7; Bad- BCL2-associated Agonist of cell Death; Bcl-2- B-cell lymphoma 2; BME- Bitter Melon Extract; Cdc2- Cell division control 2; Cdk2- Cyclin-dependent kinase 2; CDKN2A- Cyclin-dependent kinase inhibitor 2A; cIAP- Calf Intestinal Alkaline phosphatase; Cip1- CDK interacting protein 1; CLEC3B- C- type lectin domain family three member B; c-Met- tyrosine-protein kinase Met; COX-2- Cyclooxygenase-2; c-PARP- Cleaved Poly (ADP-ribose) polymerase; c-Raf-c- Rapidly Accelerated Fibrosarcoma; CTGF- Connective tissue growth factor; Cyt C- Cytochrome complex; DNMT1- DNA (cytosine-5)-methyltransferase 1; DR5- Death receptor five; ERK- Extracellular-signal-regulated kinase; FasL- Fast ligand or cell death receptor; FOXO1- Forkhead box protein O1; GSK3β- Glycogen synthase kinase three beta; H&N- Head and neck; HO-1- Heme oxygenase 1; HSP70–70 kilodalton heat shock proteins; IkBα- I-kappa-B-alpha; ITGA1- Integrin alpha-1; ITGAM- Integrin alpha M; ITGB3- Integrin beta three; JNK- c-Jun N-terminal kinase; Kip1- kinase inhibitor 1; LC3- Microtubule-associated protein 1A/1B-light chain three; MAPK- Mitogen-activated protein kinase; Mcl-1- Myeloid leukemia cell differentiation protein 1; MCM2- Minichromosome maintenance protein complex 2; MLKL- Mixed lineage kinase domain-like pseudokinase; MMP- Matrix metallopeptidase; mTOR-mammalian target of rapamycin; NF-κB- Nuclear factor kappa light chain enhancer of activated B cells; ORP150–150-kDa oxygen-regulated protein; P13K- Phosphatidylinositol 3-kinase; P70S6K- 70-kDa ribosomal protein S6 kinase; PARP- Poly-ADP ribose polymerase; JAK- Janus kinase; PPIA- Peptidylprolyl isomerase A; Rb- Retinoblastoma protein; RIPK1- Receptor-interacting serine/threonine-protein kinase 1; ROS- Reactive oxygen species; SOD- Superoxide dismutases; Sp1- Specificity protein 1; SQSTM1- Sequestosome-1; STAT3- Signal transducer and activator of transcription three; t-Bid-truncated BH3 interacting-domain death agonist; TRAIL- TNF-related apoptosis-inducing ligand; VEGF- Vascular endothelial growth factor; WNT1- Wingless-related integration site 1; XIAP- X-linked inhibitor of apoptosis protein; yH2AX- Phosphorylated X-linked inhibitor of apoptosis protein.